期刊
JOURNAL OF LEUKOCYTE BIOLOGY
卷 90, 期 5, 页码 855-865出版社
FEDERATION AMER SOC EXP BIOL
DOI: 10.1189/jlb.0211062
关键词
death receptor; lung injury; innate immunity; LPS affiliation/site
资金
- Wellcome Trust [075776, 076945]
- National Institute of Health Research Cardiovascular Biomedical Research Unit Sheffield
- MRC [G0800318, G0701932]
- Medical Research Council [G0800318, G0701932] Funding Source: researchfish
- MRC [G0701932, G0800318] Funding Source: UKRI
Novel therapeutics targeting neutrophilic inflammation are a major unmet clinical need in acute and chronic inflammation. The timely induction of neutrophil apoptosis is critical for inflammation resolution, and it is thought that acceleration of apoptosis may facilitate resolution at inflammatory sites. We previously demonstrated that a death receptor ligand, TRAIL, accelerates neutrophil apoptosis in vitro. We examined the role of TRAIL in neutrophil-dominant inflammation in WT and TRAIL-deficient mice. TRAIL deficiency did not alter constitutive neutrophil apoptosis, whereas exogenous TRAIL accelerated apoptosis of murine peripheral blood neutrophils. We compared TRAIL-deficient and WT mice in two independent models of neutrophilic inflammation: bacterial LPS-induced acute lung injury and zymosan-induced peritonitis. In both models, TRAIL-deficient mice had an enhanced inflammatory response with increased neutrophil numbers and reduced neutrophil apoptosis. Correction of TRAIL deficiency and supra-physiological TRAIL signaling using exogenous protein enhanced neutrophil apoptosis and reduced neutrophil numbers in both inflammatory models with no evidence of effects on other cell types. These data indicate the potential therapeutic benefit of TRAIL in neutrophilic inflammation. J. Leukoc. Biol. 90: 855-865; 2011.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据